The Montreal Heart Institute announces that its Research Center is launching today a COVID-19 clinical study in Canada to determine whether short-term treatment would reduce the risk of pulmonary complications and related deaths. 

The clinical study, named COLCORONA, coordinated by the Montreal Health Innovations Coordinating Center (MHICC) is funded by the Government of Quebec and supported by Pharmascience and CGI. 

In order to lower the epidemic curve and to protect its staff and customers, the ICM is implementing exceptional and temporary measures.

Visitors: On March 14, 2020, in order to protect the most vulnerable, the Government of Quebec announced the suspension of visits to all hospital centers.

EPIC Center: The EPIC Center suspends its sports activities and its secondary prevention and diabetes clinics from March 13, 2020.

The COLCOT clinical trial demonstrates that it is possible to reduce the risk of cardiovascular events with a low-cost drug already available.